Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Helse Bergen HF

Enrolment target

50

Start

20 Nov 2023

Multiple sclerosis

What is this study about?

Total number of SAEs from baseline to 24 weeks after start of study treatment

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (1)

—
Norway

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.